Michael J. Elman, MD, recaps his ALOFT study presentation at the American Society of Retina Specialists (ASRS) Annual Meeting in a short video interview.
The study, published in Ophthalmology Retina, looked at more than 2,000 ForeseeHome patients from five clinics over a 10-year period. The results were astounding:
- Patients tested an average of 5.2 times per week, an excellent compliance rate thanks to encouragement from doctors and their staff, as well as the Notal Vision Monitoring Center's engagement and support.
- Average visual acuity at wet AMD conversion was 20/39, compared to 20/83 in the American Academy of Ophthalmology's IRIS® Registry (non-ForeseeHome users).
- Most importantly, 82% of patients maintained functional vision (20/40 or better) with treatment for years after conversion.
